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Abstract
Inhibition of phosphodiesterase-4 (PDE4), an enzyme that specifically hydrolyzes cyclic adenosine
monophosphate (cAMP) increases intracellular cAMP/cAMP-response element binding protein (CREB)
signaling. Activation of this signaling is considered as an important compensatory response that decreases
motivational properties of drugs of abuse. However, it is not known whether PDE4 is involved in heroin seeking.
Self-administration of heroin (50 μg/kg/infusion) was performed under the fixed ratio 1 (FR1) schedule for 14 d
and then drug seeking was extinguished for 10 d. The progressive ratio schedule was used to evaluate the
relative motivational value of heroin reinforcement. After training, the conditioned cue or heroin priming
(250 μg/kg) was introduced for the reinstatement of heroin-seeking behavior. Pretreatment (i.p.) with rolipram
(0.03–0.3mg/kg), a prototypical, selective PDE4 inhibitor, failed to inhibit heroin self-administration under the
FR1 schedule, but decreased the reward values under the progressive ratio schedule in a dose-dependent
manner. In addition, rolipram decreased the reinstatement of heroin seeking induced by cues or heroin priming
even at the lowest dose (0.03mg/kg); in contrast, the highest dose (0.3mg/kg) of rolipram was required to
decrease sucrose reinforcement. Finally, the effects of rolipram on heroin-seeking behavior were correlated
with the increases in expression of phosphorylated CREB in the nucleus accumbens. The study demonstrated
that rolipram inhibited heroin reward and heroin-seeking behavior. The results suggest that PDE4 plays an essen-
tial role in mediating heroin seeking and that PDE4 inhibitors may be used as a potential pharmacotherapeutic
approach for heroin addiction.
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First published online 15 May 2014
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Introduction
Relapse to heroin use after abstinence is a major clinical
problem in the treatment of heroin addiction (O’Brien,
1997). Opiate withdrawal produces aversive properties,
which are considered to promote heroin-seeking and tak-
ing behaviors (Kenny et al., 2006; Zhou et al., 2009). Using
a rat model of drug relapse, we have recently found that
heroin seeking induced by re-exposure to drug-associated
cues or a heroin-priming injection persists for over two
months after withdrawal from heroin self-administration
(Zhou and Kalivas, 2008). The magnitude of heroin
seeking induced by drug-related cues is enhanced by
spontaneous withdrawal or naltrexone-precipitated with-
drawal (Kuntz et al., 2008; Zhou et al., 2009).
Cyclic adenosine monophosphate AMP (cAMP) signal-
ing plays an important role in drug abuse and depen-
dence. Infusions of cAMP signaling inhibitors such as
protein kinase A (PKA) inhibitors directly into the
nucleus accumbens (NAc), a brain region important for
motivation and reward, reduce responses of animals to
rewarding actions of cocaine and opiates (Self and
Nestler, 1995; Self and Nestler, 1998). In addition,
deficiency of the isoform (CREBαΔ) of cAMP-response
element-binding protein (CREB), the primary down-
stream target of cAMP/PKA signaling, decreases the
rewarded responses to a low dose of morphine, while
it increases the rewarding properties at a high dose of
morphine (Walters et al., 2005). The latter is supported
by the findings that overexpression of CREB in the NAc
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using viral-mediated gene transfer decreases the reward-
ing effects of cocaine and opiates, whereas expression of
a dominant negative mutant CREB (mCREB) in the
NAc increases drug rewarding effects, in addition to
producing antidepressant activity (Carlezon et al., 1998;
Pliakas et al., 2001; Barrot et al., 2002). Moreover,
drug-induced activation of CREB signaling is considered
an important compensatory response that decreases
the motivational properties of the drug (McClung and
Nestler, 2003). This is in agreement with the role of stria-
tal miR-212, which dramatically amplifies the stimulatory
effects of cocaine on CREB signaling and decreases
responsiveness to the motivational properties of the
drug (Hollander et al., 2010). Taken together, the cAMP/
PKA/CREB signal pathway is importantly involved in
rewarded responses of drugs.
Cyclic AMP is hydrolyzed by phosphodiesterase-4
(PDE4), which is critical in the control of intracellular
cAMP concentrations. PDE4 inhibitors increase intracellu-
lar cAMP and activate the cAMP/PKA signaling pathway,
leading to CREB phosphorylation (Rutten et al., 2008;
Rutten et al., 2009). It has been well documented that
PDE4 plays an important role via this signaling pathway
in the mediation of a variety of CNS functions, including
antidepressant and anxiolytic activity (O’Donnell and
Zhang, 2004; Li et al., 2009; Zhang, 2009), memory-
enhancing effects (Barad et al., 1998; Rutten et al., 2008;
Rutten et al., 2009; Li et al., 2011), and reversal of various
memory deficits (Imanishi et al., 1997; Zhang and
O’Donnell, 2000; Gong et al., 2004; Cheng et al., 2010;
Wang et al., 2012). Comparably, much less is known
about the role of PDE4 in drug dependence. Limited
studies have shown that PDE4 is involved in the physical
dependence and rewarding properties of morphine (Itoh
et al., 1998; Thompson et al., 2004). Co-administration of
rolipram, a prototypical, selective PDE4 inhibitor, and
morphine decreases the signs of morphine withdrawal
in mice and rats (Itoh et al., 1998; Gonzalez-Cuello
et al., 2007; Nunez et al., 2009). This appears to be consist-
ent with increased PDE4 activity induced by the naloxone
challenge in morphine-treated rats (Kimura et al., 2006).
These results suggest that rolipram may block the devel-
opment of morphine dependence. In addition, PDE4 inhi-
bitors may also block rewarded responses to drugs of
abuse, as evidenced by rolipram-induced reduction of
conditioning in morphine conditioned place preference
(Thompson et al., 2004) and blockade of cocaine operant
self-administration (Knapp et al., 1999). However, the
role of PDE4 in heroin dependence has not been investi-
gated. Most recently, we found that decreases in ex-
pression of pCREB in the NAc by stimulation of the
vagus nerve contribute to heroin-seeking behavior (Liu
et al., 2011). Thus, we hypothesize that rolipram benefits
the treatment of heroin seeking via activation of cAMP/
CREB signaling. In the present study, we characterized
the role of PDE4 in heroin seeking after withdrawal
by examining the effects of rolipram on heroin
self-administration and motivation of reward, and the
reinstatement of heroin seeking induced by cues or heroin
priming. The results provided novel evidence for the role
of PDE4 in heroin reward and heroin-seeking behavior.
Materials and methods
Subjects and drugs
Adult male Sprague–Dawley rats (Zhejiang Experimental
Animal Center, China), weighing 250–280 g at the begin-
ning of the experiment, were housed individually in
a temperature-controlled, ventilated colony room with
a 12-h light/dark cycle (lights on 07:00.–19:00 hours).
All experiments were conducted during the dark period
according to specifications of the National Institutes
of Health Guide for the Care and Use of Laboratory
Animals (NIH Publications No. 80–23, revised 1996).
Food and water were available ad libitum.
Heroin (diacetylmorphine HCl) was obtained from
the National Institute of Forensic Science (Beijing,
China). The heroin dose (50 μg/kg/injection) used for the
self-administration experiment was chosen on the basis
of our previous studies (Zhang et al., 2004; Zhou et al.,
2004). Heroin was dissolved in sterile saline at a concen-
tration of 0.2 mg/ml, which was prepared daily.
Rolipram (A.G. Scientific, San Diego, CA) was dissolved
in dimethyl sulfoxide (DMSO) as the stock solution
(1–3mg/ml), which was diluted before use with saline
to the concentrations needed in experiments. The final
solutions of rolipram contained less than 2% DMSO,
which was used as vehicle. Sodium pentobarbital
(30mg/ml; Sigma), heparin sodium (Qianhong
Bioscience, China), benzylpenicillin sodium (Shiyao
Bioscience, China) were dissolved in sterile saline.
Surgery procedure
Rats were anaesthetized with sodium pentobarbital
(50mg/kg, i.p.) and implanted with chronically indwell-
ing intravenous catheters as described previously (Zhou
et al., 2005; Zhou et al., 2007). The catheters were
flushed daily with 0.3 ml saline containing penicillin B
(60000 units) and heparin (5 units) to prevent potential
bacterial infections and maintain catheter patency. All
the animals were allowed to recover for at least 7 d before
the beginning of tests.
Heroin self-administration training
During the daily 4-h training session of self-
administration starting with the blue light on inside the
active nose-poke hole, the rat received a single heroin in-
fusion (50 μg/kg per infusion) following completion of
the fixed ratio 1 (FR1) schedule. Each infusion was paired
with 5-s illumination of the house light and in combi-
nation with the noise of the infusion pump, therefore
serving as discrete conditioned stimulus (CS) paired








niversity Libraries user on 03 O
ctober 2018
with the drug infusion. A timeout period was imposed
for 20 s, during which the responding produced no
programmed consequences but was still recorded.
Illumination of the blue light in the active nose-poke
signaled the end of the 20-s timeout period. Responding
in the inactive nose-poke produced no programmed
consequences. The session ended after 4 h. Each rat
received one heroin self-administration session per day
for a total of 14 d (day 1–14; Fig. 1).
Break point of heroin self-administration
The progressive ratio (PR) reinforcement schedule (i.e. the
third response requirement is four lever presses) required
animals to increase nose poking progressively for each
successive reward in the following series, within a
self-administration session. There was a timeout of 20 s
following an infusion in the PR schedule. The progression
of response requirements was calculated by the equation:
Response ratio= (5×e(0.2× infusion number)) – 5, which was
rounded to the nearest integer (Roberts and Bennett,
1993). For example, over 28 reinforcers, the nose poking
requirements were as follows: 1, 2, 4, 6, 9, 12, 15, 20, 25,
32, 40, 50, 62, 77, 95, 118, 145, 178, 219, 268, 328, 402,
603, 737, 901, 1102, and 1347. The last ratio successfully
completed was registered as the break point for that ses-
sion (Duvauchelle et al., 1998; Wang et al., 2009).
Extinction and cues or heroin-induced reinstatement
of heroin seeking
After two weeks of heroin self-administration training,
the rats underwent the extinction procedure with one
2-h session daily for 10 d (day 15–24; Fig. 1). The extinc-
tion criterion was that the last active responses are less
than 10% of the average responding on the active
nose-poke during maintenance (Lai et al., 2013). During
the extinction session, the rats were brought to the self-
administration chambers in the absence of heroin infu-
sions and the previously relevant cues. On day 25 after
the completion of extinction (Fig. 1), all rats were tested
for cues or heroin-induced reinstatement of heroin seek-
ing. In the reinstatement induced by cues, the discrete
CS were presented for 5 s, after which each active nose-
poke response resulted in another presentation of the
CS. Nose-pokes during this phase of CS reinstatement
were accumulated for over 120min. In the reinstatement
induced by heroin priming, the rats were injected with
heroin (250 μg/kg, s.c.) 10min before the beginning of
the test; each active nose-poke response also resulted in
another presentation of the CS. Nose-pokes during this
phase of heroin-primed reinstatement were also accumu-
lated for over 120min.
Oral sucrose self-administration
Twenty-four rats were trained to nose-poke for sucrose
pellets. The paradigm was similar to heroin self-
administration described above, except that rats received
a 45mg sucrose pellet (Research Diets, Inc., USA)
delivered via a sucrose cup. The operant chambers were
equipped with two holes. The active nose-poke stimulus
light was illuminated when a sucrose pellet was available.
Rats were trained to nose-poke on a fixed-ratio 5 (FR5)
schedule for a sucrose pellet for 30min each day. They
received a sucrose pellet following completion of the
ratio requirement in the active hole, which was followed
by a 20-s timeout signaled by illumination of the house
lights. After they acquired sucrose self-administration
for 10 d, the rats were randomly divided into four groups
(n=6 in each group), which were treated (i.p.) with ve-
hicle or rolipram at 0.03, 0.1, or 0.3mg/kg 60min prior
to the training session.
Specific experiment procedures
Experiment 1: Effect of rolipram on heroin self-administration
A total of 64 rats were used to start the heroin self-
administration, but three of them were excluded because
they did not meet the training standard for heroin self-
administration or extinction.
Thirty-two rats were tested for the effect of rolipram
on the reinforcement of heroin self-administration. After
heroin self-administration training for 10 d under the
FR1 schedule, the rats were randomly divided into four











Fig. 1. Schedules of rolipram (Rol) treatments and tests. Rats
were trained under the fixed ratio 1 (FR1) for
self-administration of heroin (50 μg/infusion), 4 h per session
each day for 14 d, followed by the 2-h extinction session for
10 d. During the extinction training, rats were returned to the
chambers, but no heroin or cues delivered. Experiment (Exp) 1:
On day 11, rolipram (0.03–0.3mg/kg) was given (i.p.) 60min
before the training session. Exp 2: Also on day 11, the FR1
schedule was switched to progressive ratio (PR) for the 4-h
session of heroin self-administration 60min after rolipram
treatment. Exp 3: Conditioned stimulus (CS)-induced
reinstatement on day 25 after the 14-d self-administration
followed by 10-d extinction. Rats were exposed to the CS; each
subsequent nose-poke, which was previously paired with
heroin, elicited a CS but no heroin injection. Rolipram was
given 60min before the beginning of the session, which lasted
for 2 h after initial cue exposure. Exp 4: Heroin priming
(HP)-induced reinstatement on day 25. Fifty minutes after
rolipram administration, rats were injected with heroin
(250 μg/kg, s.c.) and 10min later, the 2-h session was started.
Each active nose-poke response also resulted in another
presentation of the CS. Rats were sacrificed (Sac) once the
reinstatement session was completed.
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groups (n=8 per group), which were treated (i.p.) with
vehicle or rolipram at 0.03, 0.1, or 0.3 mg/kg 60min
prior to the FR1 training session on day 11 (Fig. 1). The
results were accumulated for 4 h. After rolipram testing,
heroin self-administration continued without drug treat-
ment during day 12–14.
Experiment 2: Effect of rolipram on heroin-induced reward
motivation
A separate set of 30 rats was tested for the effect of
rolipram on the reward motivation of heroin self-
administration. After heroin self-administration training
for 10 d under the FR1 schedule, the rats were randomly
divided into four groups and injected (i.p.) with vehicle
(n=8) or rolipram at 0.03mg/kg (n=8), 0.1 mg/kg (n=7),
or 0.3mg/kg (n=7) at 60min prior to the training session
on day 11, when the training procedure was switched to
the PR schedule for 4 h. After rolipram testing, heroin
self-administration continued without drug treatment
during day 12–14.
Experiment 3: Effect of rolipram on cue-induced reinstatement
of heroin seeking
After 14-d heroin self-administration under the FR1
schedule followed by 10-d extinction (i.e. on day 25;
Fig. 1), the rats that had been tested in Experiment 1
were tested for evaluating the effects of rolipram
on cue-induced reinstatement of heroin seeking. The
rats were injected (i.p.) with rolipram (0.03, 0.1, or
0.3 mg/kg) or vehicle (n=8 per group) 60min before
they were re-introduced into the training chambers.
When the test started, the rats were presented with the
CS, and each subsequent nose-poke in the hole previously
paired with heroin elicited a CS without heroin injection.
CS-induced reinstatement was observed for 2 h after in-
itial cues presentation.
Experiment 4: Effect of rolipram on heroin-priming-induced
reinstatement of heroin seeking
Also on day 25 after the 10-d extinction period, reinstate-
ment tests were performed in rats that had been tested in
experiment 2 to evaluate the effects of rolipram on heroin
seeking induced by heroin priming. Rats were injected
(i.p.) with rolipram at 0.03mg/kg (n=8), 0.1 mg/kg
(n=7), or 0.3 mg/kg (n=7), or vehicle (n=7) 50min prior
to heroin (250 μg/kg), which was given (s.c.) 10min before
the beginning of the 2-h testing session as described
above.
Western blot analysis
Under deep anesthesia with pentobarbital (80mg/kg), ad-
ditional rats of extinction training on day 24 and rats of
experiment 4 on day 25 were decapitated immediately
after reinstatement testing (Fig. 1) and NAc tissues were
dissected from the brain for Western blotting analysis.
Briefly, the NAc tissues were directly lyzed in the sodium
dodecyl sulfate sample buffer and incubated at 95 °C for
10min before loading on a 10% sodium dodecyl sulfate-
polyacrylamide gel. Proteins (50 μg) were separated by
electrophoresis (SDS-PAGE) before transferred to a nitro-
cellulose membrane (BioRad, USA). The membrane
was blocked in 5% milk-TBST, probed with anti-pCREB
and anti-CREB antibodies (both 1:1000; sc-7978-R for
pCREB; Santa Cruz Biotechnology Inc., USA), both in
3% milk-TBST, and then reacted with the horseradish
peroxidase-conjugated secondary antibody (1:2000) also
in 3% milk-TBST. Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) served as an internal protein control
(1:2000). Immunoreactive protein bands were detected
by using the Odyssey CLx infrared imaging system for
analyzing the changes in pCREB/CREB expression in
the NAc (for Fig. 4) during the extinction and heroin
priming. The immunoblotting bands in Experiment 4
(for Fig. 5) were analyzed by integrating densitometry
using GeneSnap and GeneTools (Chemigenius Gel
Documentation System, Syngene, UK).
Data statistics
The data from the self-administration and reinstatement
tests were analyzed separately. The mean number of infu-
sions or responses for active and inactive holes during
self-administration was analyzed using a one-way analy-
sis of vaviance (ANOVA). Newman–Keuls multiple com-
parisons were used for post-hoc analysis between groups.
Statistical significance was considered when the p value
was less than 0.05.
Results
Effect of rolipram on the heroin reinforcement and
motivation value
As shown in Fig. 2, rolipram tended to decrease the active
responses, but the one-way ANOVA revealed neither
significant changes in the active responses (F(3,28) =1.39,
p=0.27) nor inactive nose-pokes (F(3,28) =2.26, p=1.1) com-
pared to the vehicle control (Fig. 2a). The total heroin
injections received were not altered among the groups
(F(3,28) =1.69, p=0.19; Fig. 2b).
To determine whether rolipram attenuated the reward
motivation of heroin self-administration, rats were
examined under the PR schedule following rolipram
treatment. The one-way ANOVA revealed a significant
effect of rolipram on the accumulated responses of active
nose-pokes (F(3,26) =10.36, p<0.01), but not that of inactive
nose-pokes (F(3,26) =0.92, p=0.44; Fig. 2c). Post-hoc
Newman–Keuls tests indicate that rolipram at doses of
0.03–0.3 mg/kg significantly decreased the break point
of the active responses (p<0.01) in a dose-dependent
manner, while it did not affect the break point of the in-
active responses relative to the corresponding vehicle con-
trol. Rolipram at the same doses also decreased the total
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heroin injections received in a dose-dependent manner
(F(3,26) =18.22, p<0.01; Fig. 2d); at the lowest dose
(0.03mg/kg), rolipram significantly decreased the total
injections under the PR schedule (p<0.05).
Effect of rolipram on heroin seeking induced by cues
or heroin priming
To determine whether rolipram affected cue-induced
seeking behavior, we designed Experiment 3 to evaluate
the effect of rolipram on cue-induced reinstatement of
heroin seeking after extinction for 10 d. As shown
in Fig. 3a, one-way ANOVA revealed that the cue-induced
active nose-pokes were reduced by rolipram at doses of
0.03–0.3 mg/kg (F(3,28) =5.95, p=0.003), while the inactive
nose-pokes were not significantly different from the
vehicle control (F(3,28) =0.93, p=0.44). Post-hoc Newman–
Keuls comparisons indicate that rolipram at any of the
doses (0.03–0.3 mg/kg) used significantly decreased cue-
induced active responses (p<0.01; Fig. 3a).
To determine whether rolipram affected heroin
priming-induced seeking behavior, we designed Exper-
iment 4 to evaluate the effect of rolipramonheroin-induced
reinstatement of seeking following heroin-pretreatment
after 10-d extinction. One-way ANOVA revealed that
heroin-induced active nose-pokes were reduced by roli-
pram (F(3,25) =12.65, p<0.01), whereas the inactive
nose-pokes were not significantly different from the
vehicle control (F(3,25) =2.71, p=0.07; Fig. 3b). Post-hoc
Newman–Keuls comparisons indicate that rolipram at
any of the doses (0.03–0.3mg/kg) used significantly
decreased heroin-induced active responses (p<0.01).
Effect of rolipram on expression of pCREB in the NAc
To compare pCREB levels in the extinction and heroin
priming and determine whether CREB signaling was
involved in the effects of rolipram on heroin seeking,
expression of pCREB and total CREB (T-CREB) was









Rolipram (mg/kg) Rolipram (mg/kg)
















Rolipram (mg/kg) Rolipram (mg/kg)





















































Fig. 2. Effects of pretreatment with rolipram on heroin reinforcement and heroin reward values in rats. While rolipram did not
significantly change the active or inactive nose-pokes (a) or heroin infusions (b) during the training of heroin self-administration
using the FR1 schedule, it decreased the mean total responses of active nose-pokes (c) and infusion breakpoints (d) for intravenous
heroin on the progressive ratio schedule (PR) of reinforcement. Rats were administered (i.p.) vehicle, 0.03, 0.1, or 0.3 mg/kg rolipram
60min prior to the 4-h training session on day 11. Data shown are means±S.E.M; n=7–8 per group. *, **, Significant difference from
vehicle (p<0.05, p<0.01, respectively).
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rats immediately after the last extinction training and
completion of the reinstatement test induced by heroin
priming, during which rolipram or its vehicle was
given. One-way ANOVA revealed that heroin priming
produced significantly higher active responses (F(1,14) =
235.5, p<0.001) and lower levels of pCREB expression
(F(1,6) =478.8, p<0.001), without altering T-CREB levels
(F(1,6) =0.029, p=0.87) in the NAc (Fig. 4). Post-hoc
Newman–Keuls comparisons indicate a significant de-
crease in pCREB levels in the NAc (p<0.01; Fig. 4a, b) and
an increase in active responses (p<0.01; Fig. 4c), relative
to the last extinction training. Rolipram (0.03–0.3mg/kg)
increased expression of pCREB, without altering T-CREB
levels in the NAc of rats following the heroin-induced
reinstatement test, relative to the vehicle control (Fig. 5a);
one-way ANOVA revealed significance for pCREB
(F(3,8) =122.3, p<0.001), but not T-CREB (F(3,8) =1.45,
p=0.30; Fig. 5b]. Post-hoc Newman–Keuls comparisons
indicate significant increases in pCREB levels in the NAc
following treatment with rolipram at doses of 0.03, 0.1, or
0.3 mg/kg (p<0.01).
Effect of rolipram on the sucrose reinforcement
To determine whether rolipram specifically affected
heroin seeking, the effect of rolipram on sucrose self-
administration was examined in a separate set of rats
using similar procedures. One-way ANOVA revealed
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Fig. 3. Effect of rolipram on heroin seeking induced by cues or
heroin priming in rats. Rolipram decreased active, but not
inactive responses during reinstatement induced by cues (a) or
heroin priming (b). Rats were administered (i.p.) vehicle, 0.03,
0.1, or 0.3 mg/kg rolipram 60min before returned to the
operant chambers and exposed to the cues previously paired
with heroin infusions (for a) or 60min before the injection of
heroin (0.25mg/kg, s.c.) and returning to the operant chamber
(for b). The test was performed for both a and b on day 25 after
the 10-day extinction following the 14-d self-administration
training (Fig. 1). Data shown are means±S.E.M; n=8 for A or





















































Fig. 4. Expression of pCREB in the nucleus accumbens (NAc)
of rats during the extinction (Ext) and heroin priming. (a) The
representative immunoblotting bands show the expression of
pCREB, total CREB (T-CREB), or glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (the internal control) in the same
brain tissue samples. (b) Quantification analyses using Odyssey
CLx infrared imaging system show the relative levels of pCREB
and CREB proteins over GAPDH. (c) The responses during
the extinction or heroin priming. Bars shown represent
means±S.E.M; n=4; **, Significant difference from Extinction
(p<0.01).
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p<0.01) and total pellets received (F(3,20) =16.93, p<0.01),
but unaltered inactive nose-pokes (F(3,20) =0.48, p=0.69),
following treatment with rolipram (0.03–0.3mg/kg;
Fig. 6a, b). Post-hoc Newman–Keuls comparisons indicate
that rolipram significantly reduced the active responses
and the total number of sucrose pellets only at the highest
dose (0.3 mg/kg; p<0.01); at the lower doses of 0.03 and
0.1 mg/kg rolipram was not effective (Fig. 6).
Discussion
While limited studies have shown that PDE4 appears to
be involved in physical dependence and tolerance to mor-
phine (Itoh et al., 1998; Mamiya et al., 2001), there is no
evidence for the potential contribution of PDE4 to heroin
dependence. In the present study, we provided promising
demonstration that pretreatment with rolipram decreased
the motivational value of heroin under the schedule of
progressive ratio; it also inhibited heroin-seeking beha-
vior induced by cues or heroin priming. In contrast, roli-
pram did not affect heroin self-administration at doses
reducing reinstatement of heroin-seeking behavior. The
increased expression of pCREB in the NAc by rolipram
may contribute to the inhibitory action of rolipram on
heroin seeking. Our study provides novel evidence for
the role of PDE4 in heroin-seeking behavior.
The attenuation by rolipram of heroin-seeking beha-
vior appears to be independent of the sedative action of
rolipram. While rolipram produces sedation in rodents,
in particular at doses as high as 0.5–1mg/kg (Silvestre
et al., 1999a; Zhang and O’Donnell, 2000; Hu et al.,
2011), the hypoactivity induced by rolipram at the dose
of 0.3 mg/kg only lasts for approximately 20min (Wen
et al., 2012). In addition, rolipram treatment did not sign-
ificantly alter inactive responding at the doses used.
Further, rolipram at the dose (0.03mg/kg) that does not
alter the operant performance measuring depressive-like
behavior in rats (Zhang et al., 2005a) also attenuated the
reinstatement of heroin seeking induced by cues or heroin
priming. These results suggest that blockade of heroin-
seeking behavior by rolipram may not be attributed to
the sedative or antidepressant profile of rolipram.
The mechanisms whereby rolipram attenuated heroin-

































Fig. 5. Effects of rolipram on expression of pCREB in the
nucleus accumbens (NAc) of rats following the heroin-induced
reinstatement test. The representative immunobloting bands
(upper panel) show the expression of pCREB, total CREB
(T-CREB), or glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (the internal control) in the same brain tissue
samples. Quantification analyses (lower panel) show the
relative levels of pCREB and CREB proteins over GAPDH. Bars


















































Fig. 6. Effect of pretreatment with rolipram on sucrose
reinforcement in rats. Rolipram at 0.3 mg/kg decreased active,
but not inactive nose-pokes (a) and sucrose pellets (b) during
sucrose self-administration training. Rats were administered
(i.p.) vehicle, 0.03, 0.1, or 0.3 mg/kg rolipram 60min prior to
the 30-min FR5 training session. Data shown are means±S.E.M;
n=6 per group. **, Significant difference from vehicle (p<0.01).
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does not cause euphoria or dependence (Mamiya et al.,
2001), indicating that rolipram may not mimic heroin to
alter heroin-seeking behavior. However, the effects of
rolipram on rewarded responses to opioid, anxiety and
opioid withdrawal syndrome should be taken into con-
sideration. The potential action of rolipram on rewarded
responses to opioids may also be involved. Rolipram
decreases morphine or cocaine place preference con-
ditioning (Thompson et al., 2004). It also inhibits the
initiation of operant responding for cocaine, while
responding after drug-induced delays tends to be at con-
trol levels (Knapp et al., 1999). These results appear to be
consistent with inhibition of ethanol self-administration
by rolipram in rats (Wen et al., 2012). However, unaltered
heroin self-administration following treatment with roli-
pram at the doses that attenuated heroin seeking indicate
that rolipram may not alter the rewarded processes
activated by heroin under the conditions in the present
study. Interestingly, rolipram at the dose of 0.3 mg/kg
inhibited the active responses and sucrose pellet con-
sumption; this is consistent with the previous findings
that rolipram reduces response rate for food and water
(Knapp et al., 1999; O’Donnell and Frith, 1999).
Cholinergic neurons are involved heroin reward.
Enhancing either systemic or NAc acetylcholine (ACh)
function inhibits heroin reward and heroin-seeking beha-
vior (Zhou et al., 2007). ACh input into the ventral
tegmental area (VTA) from the lateral dorsal tegmental
nucleus (LDT) drives reward processes and heroin-
seeking behavior, but cholinergic modulation of VTA
neurons could be inhibited by ACh via activation of the
autoreceptors on LDT cholinergic neurons, which can
modify the reinforcing value of natural and drug rewards
(Shabani et al., 2010; Liu et al., 2012). Given that ACh is
involved in the behavioral effects of rolipram (Silvestre
et al., 1999b), rolipram may inhibit the natural reward
at least partially through the enhancement of cholinergic
transmission in the brain (Hoebel et al., 2007). Meanwhile,
other pharmacological effects of rolipram such as sedative
effects observed at 0.3 mg/kg also may contribute to its in-
hibitory effects during the 30min testing session (Knapp
et al., 1999; Wen et al., 2012).
Anxiety disorders are one of the common symptoms in
opioid withdrawal and heroin withdrawal produces
anxiety-like behavior in rats (Le Roy et al., 2013). It has
been noted that rolipram decreases withdrawal signs
and severity of withdrawal syndrome precipitated by
naloxone in morphine-dependent animals (Hamdy
et al., 2001; Mamiya et al., 2001) and produces anxiolytic
activity in rodents (Silvestre et al., 1999a; Li et al., 2009).
Moreover, rolipram alone or in combination with the clas-
sic anxiolytic diazepam attenuates morphine withdrawal
syndromes in rodents (Gonzalez-Cuello et al., 2007;
Nunez et al., 2009). We did not observe significant indica-
tions of heroin dependence in the rats under the present
conditions. Nevertheless, studies to date have shown con-
troversial results in terms of the effect of rolipram on
anxiety-like behavior; repeated treatment with rolipram
appears to be required to produce anxiolytic activity
(Silvestre et al., 1999a; Li et al., 2009). Additionally, a rela-
tively high dose (e.g. 1 mg/kg) of rolipram appears to be
required to block the withdrawal syndromes in morphine
dependent rodents (Hamdy et al., 2001; Mamiya et al.,
2001; Gonzalez-Cuello et al., 2007; Nunez et al., 2009).
In the present study, rolipram at a dose as low as 0.03
mg/kg attenuated heroin seeking. While there is no evi-
dence for the capability of rolipram at this dose to block
withdrawal behavioral manifestations in opiate depen-
dent animals, it has been demonstrated that a lower
dose (0.025mg/kg) of rolipram does effectively decrease
ethanol consumption and preference in rats (Wen et al.,
2012). Thus, further studies are needed to clarify the con-
tribution of potential anxiolytic and anti-withdrawal
actions of rolipram to attenuated heroin seeking.
It has been well documented that treatment with roli-
pram increases cAMP/PKA/CREB signaling in brain
regions including the striatum and NAc (Schneider,
1984; Barad et al., 1998; Zhang et al., 2002; Monti et al.,
2006; Rutten et al., 2008; Li et al., 2009; Rutten et al.,
2009; Li et al., 2011). This may be the neurochemical
mechanism by which rolipram attenuated heroin-seeking
behavior. More specifically, rolipram treatment increases
cAMP levels and expression of pCREB in the brain, lead-
ing to attenuation of heroin-seeking behavior, as analyzed
above. In addition, rolipram-induced increases in pCREB
in the NAc may decrease motivational responses of her-
oin, given that CREBαΔ mutant mice display increases in
opioid rewarding (Walters et al., 2005). In the particular
experiment measuring the heroin motivation in rats
under the PR reinforcement schedule, animals were
required to complete an increasing number of nose-pokes
to obtain heroin. Treatment with rolipram increased
pCREB in the NAc and consequently decreased this mo-
tivation, although it failed to affect heroin self-
administration under the FR1 schedule. Consistent with
these results, our previous study revealed that increased
expression of pCREB in the NAc induced by vagus stimu-
lation also correlates with inhibition of heroin-seeking
behavior (Liu et al., 2011).
PDE4 has four subtypes (PDE4A-D) encoded by their
distinct genes (O’Donnell and Zhang, 2004; Zhang,
2009). Since rolipram inhibits all the four subtypes at
equivalent potency (MacKenzie and Houslay, 2000;
Zhang et al., 2005b), the contribution of specific PDE4
subtypes to heroin seeking could not be addressed in
the present study. However, as the predominant PDE4
subtype in the striatum and NAc, PDE4B may be the
major subtype of PDE4 in regulating heroin-seeking beha-
vior. Further studies using PDE4-subtype knockout mice
(Zhang et al., 2002; Zhang et al., 2008) are needed to test
this prediction.
In conclusion, our study demonstrated that increased
cAMP/CREB signaling by inhibition of PDE4 decreased
heroin motivation and heroin-seeking behavior. The
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results provide promising evidence for that PDE4 can be a
target for mediating heroin seeking. PDE4 inhibitors may
be used as the novel approach for treatment of heroin
addiction, although the mechanisms of actions and the
contribution of specific PDE4 subtypes remain to be
elucidated.
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